Filtered By:
Condition: Atrial Fibrillation
Countries: Spain Health
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 92 results found since Jan 2013.
Managing uncertainty: Physicians' decision-making for stroke prevention for patients with atrial fibrillation and intracerebral haemorrhage
Conclusion Physicians described the process of deciding on stroke prevention in patients with AF post-ICH as 'challenging' due to considerable 'clinical equipoise'. Key factors that affected decision-making was patient comorbidities, functional status, and patient willingness to engage with oral anticoagulation therapy. Shared decision-making was believed to be beneficial, but physicians believed that the ultimate responsibility to decide on stroke prevention lay with the clinician.PMID:35253141 | DOI:10.1055/a-1789-4824
Source: Thrombosis and Haemostasis - March 7, 2022 Category: Hematology Authors: Elena Ivany Robyn Lotto Gregory Yh Lip Deirdre Lane Source Type: research
Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study.
Conclusion: Patients prescribed apixaban for the treatment of nonvalvular atrial fibrillation had lower rates of thromboembolic events and minor/major bleeding than patients on acenocoumarol.
PMID: 31333045 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - July 25, 2019 Category: General Medicine Tags: J Comp Eff Res Source Type: research
Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study
CONCLUSIONS: In the sample studied, half of the AF patients who suffered stroke/SE or major hemorrhagic episode had inadequate TTR and, despite this, after hospital discharge, they restarted treatment with VKA. These results highlight the need to evaluate safer and effective therapeutic alternatives in AF patients with poor TTR control after suffering a stroke/SE or major hemorrhagic episode.PMID:35120766 | DOI:10.1016/j.medcli.2021.12.004
Source: Medicina Clinica - February 5, 2022 Category: General Medicine Authors: Olga Gav ín Vanessa Rold án Pilar Llamas-Sillero Amparo Santamar ía Daniel Arum í Susana Fern ández de Cabo Source Type: research
IJERPH, Vol. 19, Pages 3182: Predictive Model and Mortality Risk Score during Admission for Ischaemic Stroke with Conservative Treatment
Conclusions: It is possible to create a predictive model of mortality for patients with ischaemic stroke from which important advances can be made towards optimising the quality and efficiency of care. The model results are available within a few minutes of admission and would provide a valuable complementary resource for the neurologist.
Source: International Journal of Environmental Research and Public Health - March 8, 2022 Category: Environmental Health Authors: Mar ía Carmen Lea-Pereira Laura Amaya-Pascasio Patricia Mart ínez-Sánchez Mar ía del Mar Rodríguez Salvador Jos é Galván-Espinosa Luis T éllez-Ramírez Fernando Reche-Lorite Mar ía-José Sánchez Juan Manuel Garc ía-Torrecillas Tags: Article Source Type: research
Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain.
CONCLUSIONS: According to this model, when costs and estimated lifetime outcomes achieved with apixaban are compared with those of ASA, apixaban was assessed to be a cost-effective treatment for the prevention of stroke in patients with NVAF in Spain.
PMID: 26832316 [PubMed - as supplied by publisher]
Source: Atencion Primaria - January 29, 2016 Category: Primary Care Authors: Escolar-Albaladejo G, Barón-Esquivias G, Zamorano JL, Betegón-Nicolás L, Canal-Fontcuberta C, de Salas-Cansado M, Rubio-Rodríguez D, Rubio-Terrés C Tags: Aten Primaria Source Type: research
Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?
ConclusionsEdoxaban is a cost-effective alternative to acenocoumarol in the prevention of stroke and systemic embolism in patients with NVAF in Spain.ResumenIntroducción y objetivosAnalizar el coste-efectividad del edoxabán frente al acenocumarol en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular (FANV) en España.MétodosModelo de Markov, adaptado a España desde la perspectiva del Sistema Nacional de Salud, que simula la evolución de una cohorte hipotética de pacientes con FANV a lo largo de toda su vida a partir de diferentes estados de salud: ictus, hemorragias y...
Source: Revista Espanola de Cardiologia - July 7, 2018 Category: Cardiology Source Type: research
Acute Stroke Care during the COVID-19 Pandemic: Reduction in the Number of Admissions of Elderly Patients and Increase in Prehospital Delays
Conclusion: We observed a reduction in the number of acute strokes and TIAs admitted during the COVID-19 period. This drop affected especially elderly patients, and despite a delay in their arrival to the emergency department, the proportion of patients treated with recanalization therapies was preserved.Cerebrovasc Dis
Source: Cerebrovascular Diseases - March 17, 2021 Category: Neurology Source Type: research
Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain
Conclusions According to this analysis, apixaban may be cost-effective in the prevention of stroke in patients with nonvalvular atrial fibrillation compared with acenocoumarol.
Source: Revista Espanola de Cardiologia - December 10, 2014 Category: Cardiology Source Type: research
Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain.
CONCLUSIONS: All three direct anticoagulants are cost-effective against acenocoumarol. Dabigatran is economically dominant over rivaroxaban and apixaban in the Spanish setting, as it is more effective and cheaper.
PMID: 28272725 [PubMed - in process]
Source: Revista de Neurologia - March 9, 2017 Category: Neurology Authors: Monreal-Bosch M, Soulard S, Crespo C, Brand S, Kansal A Tags: Rev Neurol Source Type: research
Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
CONCLUSIONS: A mixed intervention, consisting of patient education and a simple calendar reminder of drug intake, is an effective strategy to improve dabigatran therapeutic adherence in patients with NVAF. The percentage of adherence with dabigatran was high.
PMID: 29384410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 1, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke.
CONCLUSIONS: The prescription of oral anticoagulants, particularly direct oral anticoagulants, has increased from 2013 to 2019 in our Health Assistance Area. This increase might partially explain the reduction in AF-related IS.
PMID: 33326304 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
Ischaemic stroke cases set to rise 4% every year over next decade
Total of 3.7 million new cases in US, France, Germany, Italy, Spain, UK, Japan and China by 2027, trends analysis suggests Related items fromOnMedica NHS Health Check makes ‘modest’ but successful start Know your heart health risk stats as well as your PIN number, public urged Atrial fibrillation poses greater risk for women than men Diabetes, stroke and heart attack cut life expectancy England could have lowest disease burden in the world
Source: OnMedica Latest News - June 16, 2019 Category: UK Health Source Type: news
Association of oral bisphosphonates with cardioembolic ischemic stroke: a nested case-control study
Conclusion: The use of oral bisphosphonates increases specifically the odds of cardioembolic IS, in a duration-dependent manner, while leaves materially unaffected the odds of non-cardioembolic IS.
Source: Frontiers in Pharmacology - May 26, 2023 Category: Drugs & Pharmacology Source Type: research
